Immix Biopharma

Immix Biopharma completed the six-patient Phase 1b safety run-in for NXC-201, a CAR-T therapy for AL Amyloidosis, accelerating U.S. enrollment. NXC-201, the only CAR-T therapy in development for this condition, showed no neurotoxicity and high complete response rates in prior studies. Next update expected Q1 2025.

All four patients treated with NXC-201 normalized disease markers within 30 days, with two classified as complete responders (CR) and two bone marrow MRD negative (10^-6). Immix Biopharma expects the remaining two to be confirmed as CRs soon. The company plans to provide a program update in H1 2025 and will host a conference call on Dec 19, 2024.

Immix Biopharma reported positive clinical data from the first four patients in the NEXICART-2 U.S. trial of NXC-201 for relapsed/refractory AL Amyloidosis. All patients normalized disease markers within 30 days, with two achieving complete response and two showing bone marrow MRD negativity. The company plans a conference call on Dec 19, 2024, and a program update in H1 2025.

Immix Biopharma announced positive clinical data from the NEXICART-2 trial for NXC-201, a CAR-T therapy for AL Amyloidosis. All four patients normalized disease markers within 30 days, with two achieving complete response and two bone marrow MRD negative. No severe adverse effects were reported. Next update expected H1 2025.

Immix Biopharma announced promising initial results from its NEXICART-2 trial for CAR-T cell therapy NXC-201 in AL Amyloidosis patients, showing normalized disease markers and improved heart function. The trial continues with plans for updates in 2025. NXC-201 has Orphan Drug Designation by FDA and EMA. Immix maintains a strong liquidity position despite stock decline.

Immix Biopharma announced positive early results from its Phase 1b/2 NEXICART-2 trial for NXC-201 in treating AL Amyloidosis. All four patients normalized disease markers within 30 days, with two complete responders and two MRD negative. The therapy was well-tolerated, with no severe adverse events. Further updates are expected in 2025.

Immix Biopharma's CAR-T cell therapy NXC-201 shows a 75% complete response rate in relapsed/refractory AL Amyloidosis patients, with a favorable safety profile. NEXICART-1 trial results published in JCO highlight its potential, with ongoing U.S. studies focusing on patients with preserved heart function.

NXC-201, a CAR-T cell therapy, showed a 75% complete response rate in relapsed/refractory AL Amyloidosis patients in the NEXICART-1 trial. Immix Biopharma's ongoing U.S. NEXICART-2 trial focuses on patients with preserved heart function, aiming to evaluate NXC-201's safety and efficacy further.

Immix Biopharma announced updated Phase 1/2 data for CAR-T therapy NXC-201, showing a 75% complete response rate in relapsed/refractory AL Amyloidosis patients. The therapy demonstrated a 94% overall response rate and 62% organ response rate, with no ICANS cases. Despite promising results, the company faces financial challenges, with a -63% year-to-date return. NXC-201 has received Orphan Drug Designation in the US and EU.